Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

11 results about "Immune compromised" patented technology

Immune compromise, also referred to as immunocompromise or immunosuppression, is a condition in which the immune system does not work as well as it does in normal healthy workers. Immune compromised personnel are at higher risk of illness and/or more serious side effects of illness caused by an infectious disease.

AAVR knockout mouse in combination with human liver chimerism and methods of use and production of the same

The present disclosure provides an immunodeficient or immune-impaired chimeric non-human animal with a deletion or impairment of adeno-associated virus receptor (AAVR), comprising human hepatocytes, methods for preparing the chimeric non-human animal comprising human hepatocytes and methods of utilizing the chimeric non-human animal comprising human hepatocytes to evaluate transduction efficiency of adeno-associated viruses (AAV), and determine mechanism of inhibition / modification of AAV transduction in human hepatocytes.
Owner:AVACHROME INC

Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a PD-1 inhibitor

The present disclosure provides methods for treating or inhibiting the growth of a tumor, including selecting a patient with cancer, wherein the patient is immunosuppressed or immunocompromised, and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an anti-PD-1 antibody, such as cemiplimab or a bioequivalent thereof). In certain embodiments, the cancer is skin cancer, such as cutaneous squamous cell carcinoma.
Owner:REGENERON PHARMACEUTICALS INC

Variants of human programmed cell death protein (PD-1)

PCT designated stage expiredWO2025049019A1Cell receptors/surface-antigens/surface-determinantsAntibody mimetics/scaffoldsDiseaseImmune compromised
The disclosure provides amino acid sequence variants of programmed cell death protein 1 (PD-1) that can bind to either or both of its ligands, PDL-1 or PDL-2. The disclosure relates to ligand-binding fragments of the PD-1 variant sequences, conjugates, and related compositions and formulations. The disclosure also relates to methods for using the sequences, e.g., PD-1 variants and ligand-binding fragments thereof, in the treatment of checkpoint pathway-related diseases, disorders, and conditions including cell proliferative diseases such as cancer, as well as diseases, disorders, and conditions associated with immune deficiency, immune insufficiency, and / or subjects who are immune compromised.
Owner:JECHO LABORATORIES INC

Multifunctional PD1 fusion proteins

PCT designated stage expiredWO2025085590A1Cell receptors/surface-antigens/surface-determinantsAntibody mimetics/scaffoldsDiseaseImmune compromised
The disclosure provides a fusion protein comprising one or more of programmed cell death protein 1 (PD1) sequence, cluster of differentiation 80 (CD80) sequence, an IgG Fc region and compositions thereof. The disclosure also relates to methods for using the fusion proteins, in the treatment of checkpoint pathway-related diseases, disorders, and conditions including cell proliferative diseases such as cancer, as well as diseases, disorders, and conditions associated with immune deficiency, immune insufficiency, and / or subjects who are immune compromised.
Owner:JECHO LABORATORIES INC

Application of human milk oligosaccharide composition in medicine preparation

The invention relates to the technical field of biological medicines, and particularly provides application of a human milk oligosaccharide composition in preparation of medicines. According to the human milk oligosaccharide composition and the preparation method thereof, the 2 '-fucosyllactose, the galactooligosaccharide and the short-chain fructooligosaccharide are precisely proportioned, so that the provided composition has the effect of enhancing immunity, and the verification of the medicinal value of the human milk oligosaccharide composition is realized. Specifically, the human milk oligosaccharide composition provided by the invention not only can enhance the immunity of normal organisms, but also can be used for repairing the immune regulation ability of immunocompromised or immune impaired organisms.
Owner:INNER MONGOLIA MENGNIU DAIRY IND (GROUP) CO LTD

Compositions and methods for diagnosing susceptibility to autism spectrum disorder (ASD), reducing the likelihood of developing ASD, and / or treating ASD

ActiveUS12150966B2Nervous disorderDispersion deliveryImmune compromisedAntiviral drug
The present invention provides compositions and methods for improving the quality of life for a subject, particularly a child, diagnosed with autism spectrum disorder (ASD). In preferred embodiments, a supplement composition comprising natural or naturally-derived ingredients is delivered to a subject in the form of a chocolate bar or other candy alongside administration of an antiviral medication. Advantageously, the composition and methods can improve the immune health of the subject, along with other signs and symptoms associated with ASD, infections and other immunocompromising conditions.
Owner:FLAASK LLC

In vivo models of human small intestine using pluripotent stem cells and methods of making and using same

To provide methods of making a vascularized hollow organ derived from a human intestinal organoid (HIO).SOLUTION: Provided is a method of making a vascularized hollow organ, the method comprising a step of a) engrafting a human intestinal organoid (HIO) into an immune compromised organism, preferably a mammal, preferably a mammal having no immune response, preferably a mammal having severe combined immunodeficiency disorder (SCID); where the HIO is obtained from human embryonic stem cells (ESCs) and / or induced pluripotent stem cells (iPSCs) where the HIO forms mature intestinal tissue during the engrafting step.SELECTED DRAWING: None
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI

Method for diagnosing immunocompromise in workers exposed to mixed aerosols containing crystalline silicon dioxide from 10 to 70% and metals in solid phase

ActiveRU2865345C1Immune compromisedVenous blood
FIELD: occupational medicine.SUBSTANCE: used to diagnose immunocompromise in workers exposed to mixed aerosols containing crystalline silicon dioxide from 10 to 70% and metals in the solid phase. Samples of venous blood and smears from the mucous membrane of the pharynx are taken. In the presence of Streptococcus pneumoniae DNA in scrapings from the mucous membrane of the pharynx and with the level of immunoglobulin M in the blood serum≤ 1.7 g / l is used to diagnose immunocompromise in workers exposed to mixed aerosols containing crystalline silicon dioxide from 10 to 70% and metals in the solid phase.EFFECT: method provides the possibility of selecting immunocompromised workers exposed to industrial mixed aerosols for priority vaccination against pneumococcal infection at the stage of periodic medical examination, by determining the level of immunoglobulin M in the blood serum and Streptococcus pneumoniae DNA in swabs from the mucous membrane of the pharynx.1 cl, 1 tbl, 1 ex
Owner:FEDERALNOE BYUDZHETNOE UCHREZHDENIE NAUKI EKATERINBURGSKIJ MEDITSINSKIJ NAUCHNYJ TSENTR PROFILAKTIKI I OKHRANY ZDOROVYA RABOCHIKH PROMPREDPRIYATIJ FEDERALNOJ SLUZHBY PO NADZORU V SFERE ZASHCHITY PRAV POTREBITELEJ I BLAGOPOLUCHIYA CHELOVEKA FBUN EMNTS POZRPP ROSPOTREBNADZORA

Systems to produce B cells genetically modified to express selected antibodies

Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and / or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.
Owner:FRED HUTCHINSON CANCER CENT

Implantable scaffolds for immunotherapeutic and other uses

PCT designated stage expiredWO2023114418A9Powder deliverySsRNA viruses positive-senseAntigenImmune compromised
An implantable or injectable scaffold comprising an antigen, a T memory cell inducer, and other optional components is provided for use in enhancing the immune response to the antigen, in particular for subjects who are elderly, immunosenescent and / or immunocompromised, or undergoing cancer therapy. Coronavirus SARS-CoV-2 has caused millions of confirmed cases and hundreds of thousands of deaths. However, there is no effective drug treatment, and vaccine is in great need to control the spread of such highly infectious virus.
Owner:RGT UNIV OF CALIFORNIA

Application of human milk oligosaccharide composition in the preparation of medicines

The present invention relates to the field of biomedicine technology, and specifically provides the use of a human milk oligosaccharide composition in the preparation of a drug. The present invention provides a composition that has the effect of enhancing immunity by accurately proportioning 2'-fucosyllactose, oligogalactose and short-chain oligofructose, thereby realizing the verification of the medicinal value of the human milk oligosaccharide composition. Specifically, the human milk oligosaccharide composition provided by the present invention can not only enhance the immunity of a normal body, but also can be used to repair the immunoregulatory ability of an immunocompromised or immunocompromised body.
Owner:INNER MONGOLIA MENGNIU DAIRY IND (GROUP) CO LTD